

Spain

Population (January 2013):	46 727 890
Human development Index (2013):	0.869
HAV vaccine recommendations:	HAV vaccination is universally recommended and covered for children aged between 15 and 24 months in Ceuta and Melilla (13 years old catch-up), and; for children aged between 12 months and 6 years old in Catalonia (11-12 years old catch-up). Vaccination is recommended for: <ol style="list-style-type: none"> 1. travellers to endemic areas 2. patients with chronic hepatic disease (including asymptomatic VHB patients) 3. household contacts of an HAV patient 4. haemophiliacs 5. institutionalised children 6. people with occupational exposure, e.g. nursery staff, healthcare workers, sewage workers 7. MSM 8. PWID.
Seroprevalence studies by quality score:	score 0: 19 studies; score 1: 21 studies; score 2: 13 studies
Seroprevalence studies timeframe:	1977–2013

Seroprevalence assessment: **very low**

Incidence assessment: **low**

Susceptibility in adults: **moderate**

A total of 24 studies were included for the period 1975–1990 and all estimated a HAV seroprevalence above 50% by age 30 years. On the other hand, only three studies of lower quality estimated the seroprevalence to be over 50% by age of 15 (Figure 1).

For the period 1991–1999 we included 31 studies. Seven of these reported seroprevalence by age 30, three estimated seroprevalence levels above 50% and four below 50%. No study estimated seroprevalence over 50% by age 15 (Figure 1).

A total of 15 studies were included from 2000 onwards. All estimated a HAV seroprevalence at less than 50% by 30 years old and less than 20% at the age of 15. Therefore, Spain, likely transitioned from low to very low endemicity in the 1990s and remains a very low endemicity country after 2000.

Spain_Table 1. Hepatitis A seroprevalence level by time period


	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

Incidence data (Figure 2) are available from TESSy and two published studies since 2005. The incidence has been low to very low, ranging from 1.1 to 5.5 per 100 000 over the period.


The susceptibility among adults is moderate, as susceptibility levels are around 60–70%, by 30 years of age however the susceptibility quota steeply decreases and less than 20% are susceptible after age 45.

Spain_Figure 1 (panel a). Summary of seroprevalence in Spain, by age and time period.


Panel a.1: 1975–1989




Panel a.2: 1990–1999




Panel a.3: 2000–2013



Spain_Figure 1 (panel b). Summary of seroprevalence in Spain, by age and time period (1975-2013).



Spain_Figure 2. Reported incidence of hepatitis A, Spain, 2005–2013.

Bibliography

- Amela C, Pachon I, Bueno R, de Miguel C, Martinez-Navarro F. Trends in hepatitis A virus infection with reference to the process of urbanization in the greater Madrid area (Spain). *Eur J Epidemiol.* 1995 Oct;11(5):569-73.
- Arteaga-Rodriguez A, Carrasco-Garrido P, de Andres AL, de Miguel AG, Santos J, Jimenez-Garcia R. Changes in the epidemiology of hepatitis A in Spain (2005-2008): trends of acute hepatitis A hospitalizations, comorbidities, and costs associated with the hospitalization. *Eur J Gastroenterol Hepatol.* 2010 Nov;22(11):1284-9.
- Bayas JM, Bruguera M, Vilella A, Carbo JM, Vidal J, Navarro G, et al. [Prevalence of hepatitis B and hepatitis A virus infection among health sciences students in Catalonia, Spain]. *Med Clin (Barc).* 1996 Sep 14;107(8):281-4.
- Bolumar F, Giner-Duran R, Hernandez-Aguado I, Serra-Desfilis MA, Rebagliato M, Rodrigo JM. Epidemiology of hepatitis A in Valencia, Spain: public health implications. *J Viral Hepat.* 1995;2(3):145-9.
- Bruguera M, Salleras L, Plans P, Vidal J, Navas E, Dominguez A, et al. [Changes in seroepidemiology of hepatitis A virus infection in Catalonia in the period 1989-1996. Implications for new vaccination strategy]. *Med Clin (Barc).* 1999 Mar 27;112(11):406-8.
- Buti M, Campins M, Jordi R, Navas E, Cotrina M, Llobet E, et al. [Seroepidemiology of hepatitis A virus infection in medical and nursing students. The role of vaccination]. *Gastroenterol Hepatol.* 1996 Apr;19(4):199-202.
- Carreno Garcia V, Gonzalez Alonso R, Porres Cubero JC, Ortiz Masllorens F, Martin Calderin F, Hernandez Guio C. [Prevalence of anti-HAV in the Spanish population]. *Rev Esp Enferm Apar Dig.* 1983 Sep;64(3):187-90.
- Cilla G, Perez-Trallero E, Artieda J, Serrano-Bengoechea E, Montes M, Vicente D. Marked decrease in the incidence and prevalence of hepatitis A in the Basque Country, Spain, 1986-2004. *Epidemiol Infect.* 2007 Apr;135(3):402-8.
- Cilla G, Perez-Trallero E, Marimon JM, Erdozain S, Gutierrez C. Prevalence of hepatitis A antibody among disadvantaged gypsy children in northern Spain. *Epidemiol Infect.* 1995;115(1):157-61.
- Dal-Re R, Aguilar L, Coronel P. Current prevalence of hepatitis B, A and C in a healthy Spanish population. A seroepidemiological study. *Infection.* 1991 Nov-Dec;19(6):409-13.
- Dal-Re R, Garcia-Corbeira P, Garcia-De-Lomas J. A large percentage of the Spanish population under 30 years of age is not protected against hepatitis A. *J Med Virol.* 2000;60(4):363-6.
- Departamento de Sanidad y Consumo. I encuesta de seroprevalencia de la comunidad autónoma del País Vasco. San Sebastian: Administración de la Comunidad Autónoma del País Vasco, 2011 1 December 2011. Report No.
- Dominguez A, Bruguera M, Plans P, Costa J, Salleras L. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization. *J Med Virol.* 2004 Jun;73(2):172-6.
- Dominguez A, Bruguera M, Plans P, Espunes J, Costa J, Plasencia A, et al. Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study. *BMC Infect Dis.* 2007;7:73.

15. Garcia Erce J, Solano Bernad VM, Ferrer Torres J, Gimeno Lozano JJ. [Seroprevalence of hepatitis A in Aragonese donors]. *Sangre (Barc)*. 1996 Dec;41(6):484-5.
16. Garcia-Fulgueiras A, Rodriguez T, Tormo MJ, Perez-Flores D, Chirlaque D, Navarro C. Prevalence of hepatitis A antibodies in southeastern Spain: a population-based study. *Eur J Epidemiol*. 1997 Jun;13(4):481-3.
17. Gil A, Gonzalez A, Dal-Re R, Aguilar L, Rey Calero J. [Seroprotection against hepatitis A, measles, rubella, and parotiditis in an urban school population]. *Med Clin (Barc)*. 1991 May 11;96(18):681-4.
18. Gil A, Gonzalez A, Dal-re R, Dominguez V, Astasio P, Aguilar L. Detection of antibodies against hepatitis A in blood spots dried on filter paper. Is this a reliable method for epidemiological studies? *Epidemiol Infect*. 1997;118(2):189-91.
19. Gil A, Gonzalez A, Dal-Re R, Ortega P, Dominguez V. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. *J Infect*. 1998 Jan;36(1):53-6.
20. Gil Miguel A, Gonzalez Lopez A, Dal-re R, Dominguez Rojas V. [A serial questionnaire on the prevalence of hepatitis A antibodies in adolescents in urban area: comparative study (1990-1995)]. *Aten Primaria*. 1996 Dec;18(10):584, 6.
21. Gil Miguel A, Gonzalez Lopez A, San Martin Rodriguez M. [Prevalence of hepatitis A antibodies in 6-7 year-old children: follow-up study 1990-1998]. *An Esp Pediatr*. 1999 Nov;51(5):569-70.
22. Gonzalez A, Bruguera M, Calbo Torrecillas F, Monge V, Dal-Re R, Costa J. [Seroepidemiologic survey of hepatitis A antibodies in the young adult Spanish population. Spanish Study Group on hepatitis A (1)]. *Med Clin (Barc)*. 1994 Oct 15;103(12):445-8.
23. Gonzalez Praetorius A, Rodriguez-Avial C, Fernandez C, Perez Pomata MT, Gimeno C, Bisquert J. [Incidence and risk factors for hepatitis A in the province of Guadalajara (Spain)]. *Gastroenterol Hepatol*. 2002 Apr;25(4):230-4.
24. Gonzalez-Quintela A, Gude F, Boquete O, Aguilera A, Rey J, Meijide LM, et al. Association of hepatitis A virus infection with allergic sensitization in a population with high prevalence of hepatitis A virus exposure. *Allergy: European Journal of Allergy and Clinical Immunology*. 2005;60(1):98-103.
25. Jimenez Rodriguez-Vila M, Hernandez Gajate M, Pascual Martin ML, Martin Rojo M, Fernandez Alonso MC, Gomez Arranz A, et al. [Antibody titers against the hepatitis A virus in a healthy population from an urban health area]. *Aten Primaria*. 1992 Jan;9(1):10-2.
26. Junquera S, Mateos M, Lasa E, Chacon J, Baquero F. [Seroepidemiologic study of hepatitis A in the community of Madrid during the year 2002]. *Enferm Infecc Microbiol Clin*. 2004 Oct;22(8):448-51.
27. Lasheras Lozano ML, Gil Miguel A, Santos Santos M, Rey Calero J. [The seroepidemiology of the hepatitis A virus in children and adolescents]. *Aten Primaria*. 1994 Jan;13(1):36-8.
28. Lopez-Izquierdo R, Udaondo MA, Zarzosa P, Garcia-Ramon E, Garcinuno S, Bratos MA, et al. [Seroprevalence of viral hepatitis in a representative general population of an urban public health area in Castilla y Leon (Spain)]. *Enferm Infecc Microbiol Clin*. 2007 May;25(5):317-23.
29. Marti Bartolin M, Barreda Barreda V, Manez Gutierrez E, Forcada Segarra JA. Hepatitis A seroprevalence among active population in Castellon in 2010. *Vacunas*. 2013.
30. Martinez IM, Budino AA. Prevalence of antibodies against the A, B, C, and E hepatitis viruses in the rural child population in northern Extremadura. *An Esp Pediatr*. 1996;45(2):133-6.
31. Menendez MT, Cordero M, Viejo G, Miguel D, Malo de Molina A, Otero C. [The serum markers in the pregnant population of the basic health area of El Natahoyo (Gijon)]. *Aten Primaria*. 1996 Jun 15;18(1):17-21.
32. Morales JL, Huber L, Gallego S, Alvarez G, Diez-Delgado J, Gonzalez A, et al. A seroepidemiologic study of hepatitis A in Spanish children. Relationship of prevalence to age and socio-environmental factors. *Infection*. 1992 Jul-Aug;20(4):194-6.
33. Moreno M, Perez Perez A, Martinez M, Agudo S, Lopez-Brea M, Casal C. Retrospective study of increasing incidence of acute hepatitis A in Area 2 of Madrid. A report from the microbiology department at a university hospital, Madrid, Spain. *Clin Microbiol Infect*. 2010;16:S698.
34. Oviedo M, Munoz MP, Dominguez A, Carmona G. Estimated incidence of hepatitis A virus infection in Catalonia. *Ann Epidemiol*. 2006 Nov;16(11):812-9.
35. Perez-Trallero E, Cilla G, Urbieto M, Dorransoro M, Otero F, Marimon JM. Falling incidence and prevalence of hepatitis A in Northern Spain. *Scand J Infect Dis*. 1994;26(2):133-6.
36. Rivera F, Ruiz J, Garcia de Pesquera F. [Evolution of the prevalence of hepatitis A antibody in Seville]. *Aten Primaria*. 1998 Feb 15;21(2):97-100.
37. Rodriguez-Iglesias MA, Perez-Gracia MT, Garcia-Valdivia MS, Perez-Ramos S. Seroprevalence of hepatitis A virus antibodies in a pediatric population of southern Spain. *Infection*. 1995 Sep-Oct;23(5):309.
38. Ruiz Moreno M, Garcia Aguado J, Carreno Garcia V, Alvarez Sala L, Rincon Victor P, Lopez-Linares del Prado M, et al. [Prevalence of hepatitis caused by A, B and D virus in children]. *An Esp Pediatr*. 1988 Nov;29(5):357-62.

39. Sanchez Quijano A, Lissen Otero E, Garcia de Pesquera F. Prevalence of serological markers of the hepatitis A and B viruses in volunteer blood donors in Sevilla. *Gastroenterol Hepatol*. 1983;6(2):62-6.
40. Santana OE, Rivero LE, Liminana JM, Hernandez LA, Santana M, Martin AM. [Seroepidemiological study of hepatitis A in Gran Canaria (Spain)]. *Enferm Infecc Microbiol Clin*. 2000 Apr;18(4):170-3.
41. Servizo Galego de Saude. Boletín Epidemiolóxico de Galicia. Xunta de Galicia, 2014 September 2014. Report No.
42. Soriano R, Tiberio G, Martinez Artola V, Casares N, Berrade F. [Hepatitis A seroprevalence in Navarra]. *Rev Clin Esp*. 2004 Mar;204(3):145-50.
43. Suarez A, Navascues CA, Garcia R, Peredo B, Miguel D, Menendez MT, et al. [The prevalence of markers for the hepatitis A and B viruses in the population of Gijon between 6 and 25 years old]. *Med Clin (Barc)*. 1996 Apr 6;106(13):491-4.
44. Suarez A, Viejo G, Navascues CA, Garcia R, Diaz G, Otero L, et al. Serological markers of hepatitis A, B and C in first year student nurses. *Rev Esp Enferm Dig*. 1998 Jul;90(7):480-6.
45. Suarez A, Viejo G, Navascues CA, Garcia R, Diaz G, Saro C, et al. [The prevalence of hepatitis A, B and C viral markers in the population of Gijon between 26 and 65 years old]. *Gastroenterol Hepatol*. 1997 Aug-Sep;20(7):347-52.
46. V V, M B, JM H-S, R. J, A. P, R. E, et al. Prevalencia de los anticuerpos contra el virus de la hepatitis A en la poblacion general. Estudio comparativo 1977-1985. *Med Clin (Barc)*. 1987;88:144-6.
47. Vargas V, Buti M, Hernandez-Sanchez JM, Jardi R, Portell A, Esteban R, et al. [Occurrence of antibodies against hepatitis A virus in general population. Comparative study, 1977-1985]. *Med Clin (Barc)*. 1987 Jan 31;88(4):144-6.